Instructional Courses

• HNSCC Cases for AHNS – 3 Cases Presentation


• SIERRA B: Systemic Therapy in SCCHN


• SIERRA B: The Role of Systemic Therapy in Locally Advanced Squamous Cell Carcinoma of the Head & Neck


• SIERRA B: Quality of Head & Neck Cancer Care: How Do We Improve?


• SIERRA H: Electronic Medical Record Systems in a Head & Neck Oncologic Practice


• SIERRA H: Screening and Early Diagnosis of Oral Cancer


• SIERRA H: What’s New in Padiotherapy for Head & Neck Cncer?


• SIERRA I: IRB/GRANTS – Institutional Review Board 101


• SIERRA I: Decision making in the Management of the Mandible in Oral Cancer


• SIERRA I: Nuts and Bolts of Tissue Banking


• SIERRA I: Quality of Life, Symptom Control and Functional Outcomes


• SIERRA I: Tumor Board: Oral Cavity "The Role of Sentinel Node Biopsy"


• SIERRA I: IRB/GRANTS – Get Your Grant Funded


• SIERRA I: The Abstrusity of QOL


• NOB HILL A: Multidisciplinary Head & Neck Cancer Care in the Community


• NOB HILL A: Surgical Options for Distant Metastases


• NOB HILL A: Multidisciplinary Management of Head & Neck Cancer Care in the Community Setting


• YERBA SALON 10-11: Linear Stapler in Total Laryngectomy


• YERBA SALON 10-11: Mini-course on Surgical Technique for Larynx


• YERBA SALON 10-11: Introduction to Oncogenomics/Proteomics 101


• YERBA SALON 10-11: Post Operative Radiotherapy for Head & Neck Tumors


• YERBA SALON 10-11: Minimally Invasive Thyroid. Videoassisted Thyroidectomy


• YERBA SALON 10-11: Videoassisted Thyroidectomy: Lessons After 2 Years


• YERBA SALON 10-11: Robotics Neck Surgery: a Systematic Approach to Implementing a New Surgical Technique


• YERBA SALON 10-11: Adjuvant Radiation and Chemotherapy in the Treatment of Squamous Cell Carcinoma of the Head & Neck


• YERBA SALON 10-11: Transoral Robotic Surgery (TORS) Program - From the Bench to the Bedside


• YERBA SALON 12-13: Surgical Technique on Salivary Glands


• YERBA SALON 12-13: Speech and Swallowing Rehabilitation


• YERBA SALON 12-13: Surgical Eintervention for Dysphagia and Aspiration


• YERBA SALON 12-13: Damage Control


• YERBA SALON 12-13: Instructional Session: Salivary Gland Surgery


• YERBA SALON 12-13: Sonographic Evaluation of Lymph Nodes with Head & Neck Cancer


• YERBA SALON 14: The Search for Cancer Stem Cell in Head & Neck Squamous Cell Carcinoma


• YERBA SALON 14: Combined Therapy for Squamous Cancer of the Oropharyrnx


• YERBA SALON 14: Combined Therapy for Oropharyrnx Cancer


• YERBA SALON 14: Target Therapy 101


• YERBA SALON 15: National Reimbursement Scene for Physicians


• YERBA SALON 15: Stereolithographic Modeling for Mandibular Reconstruction


• YERBA SALON 15: Reimbursement in Head &Neck Oncologic Surgery


• YERBA SALON 15: Management of the Neck in the Treatment of Oropharyngeal Cancer


• YERBA SALON 15: Radiotherapy for Hypopharynx Cancer
• YERBA SALON 15: Cancer of the Hypopharynx

• YERBA SALON 1-2: Tumor Volume as Outcome Predictor in Chemoradiation for Advanced Head & Neck Cancer


• YERBA SALON 1-2: CI-1040 Inhibits Growth of Papillary Thyroid Carcinoma


• YERBA SALON 1-2: IRX-2, a Multi-targeted Biologic, Protects T Cells from Tumor-induced Cell Death


• YERBA SALON 1-2: Does Post-treatment Surveillance Improve survival in Head & Neck cancer Patients?


• YERBA SALON 1-2: HPV-16 Influence on Oropharyngeal Cancer Treated in a Large Multidisciplinary Setting


• YERBA SALON 1-2: Involvement of Rho C in Head & Neck Cancer Metastasis


• YERBA SALON 1-2: Levels of CD44, a Head & Neck Cancer Stem Cell Marker, Correlate with Tumor Aggressiveness


• YERBA SALON 1-2: Cetuximab Mediated Lysis is regulated by Polymorphic FcγR-IIIa NK Cells


• YERBA SALON 1-2: DAHANCA 10 – a Randomized Study of Aranesp® as Modifier of Radiotherapy in Patients with Primary HNSCC


• YERBA SALON 1-2: HPV-16 E6 and E7 Transactivate a Human Endogenous Retroviral Superantigen that is Expressed in HPV+OSCC


• YERBA SALON 1-2: Phase II Study of Bevacizumab, Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head & Neck


• YERBA SALON 1-2: CWRU 1301: Phase I Study of the EGFR Tyrosine Kinase Inhibitor Erlotinib (Tarceva) in Combination with Docetaxel & Radiation


• YERBA SALON 1-2: Detection of Promoter Hypermethylation of Multiple Genes in tumor and Serum Samples of Patients with HNSCC


• YERBA SALON 1-2:  The Effect of Over Expression of the Intrinsic Hypoxia Markers HIF1a, CA-IX and GLUT-1 on local Recurrence in T1/T2 Glottic Laryngeal Carcinoma Treated with Radiation Therapy


• YERBA SALON 1-2: Noninvasive Detection of HPV & Associated Genetic Alteration in Squamous Head & Neck Cancer


• YERBA SALON 1-2: Quantitative Methylation Analyses of Resection Margins Predict Local Recurrences and Disease specific survivals in Head & Neck Squamous Cell Carcinomas


• YERBA SALON 1-2: Engineering an Artificial Salivary Gland


• YERBA SALON 3-4: Functional Imaging Evaluation of Response to Therapy


• YERBA SALON 3-4: ASHNR Panel: Post-treatment Imaging and Complications


• YERBA SALON 3-4: Novel Targeted Therapeutic Approaches to Squamous Cell Carcinoma of the Head & Neck


• YERBA SALON 3-4: Pitfalls in PET/CT/MR of the Post-treatment Head & Neck Cancer Patients


• YERBA SALON 3-4: Radiation Therapy Planning Novel PET Tracers


• YERBA SALON 3-4: HPV16 and Oropharyngeal Cancer


• YERBA SALON 3-4: FDG-PET for Head & Neck Cancer: Initial Starting


• YERBA SALON 5-6: Genetic Classification of Head & Neck Cancer


• YERBA SALON 5-6: Proteomic Profiling to Predict Chemotherapy Response in HNSCC


• YERBA SALON 5-6: Head & Neck Cancer Virology


• YERBA SALON 5-6: Oral HPV Infection


• YERBA SALON 5-6: EBV and NPC: Diagnostic and Therapeutic Opportunities


• YERBA SALON 5-6: Utilization of Protein Arrays for Head & Neck Cancer Analyses


• YERBA SALON 5-6: HPV as a Risk Factor for Head & Neck Cancer


• YERBA SALON 5-6: Expression Array Analyses to Predict HNSCC Behavior


• YERBA SALON 5-6: Genomics/Proteomics in Head & Neck Cancer


• YERBA SALON 10-11: Sentinel Node Biopsy in Oral/Oropharyngeal Squamous Cell Cancer


• YERBA SALON 10-11: Sentinel Lymph Node Biopsy for Squamous Cell Carcinoma of the Oral Cavity


• YERBA SALON 10-11: TH1/TH2 CD4+ T Helper Responses Against Wild-type Sequence P53 Peptides in HLA-DP5 Patients with Head & Neck Cancer


• YERBA SALON 10-11: The Important of Immunohistochemistry in Sentinel Lymph node Analysis in Head & Neck Cancer


• YERBA SALON 10-11: Epigenetic Effect of Gossypol in In-vitro Suppression of Head & Neck Squamous Cell Carcinoma


• YERBA SALON 10-11: Promoter Hypermethylation and Hypomethylation in Oral Squamous Cell Carcinoma


• YERBA SALON 10-11: Ligands on Head & Neck Squamous Cell Carcinoma Mediate Low Shear-resistant Binding to Lymphocytes via L-selectin


• YERBA SALON 10-11: Interleukin 8 is Regulated by Transcription Factor ATF2 in HNSCC


• YERBA SALON 10-11: Selective Versus Comprehensive Neck Dissection after Chemoradiation Therapy for Advanced Head & Neck Squamous Cell Carcinoma


• YERBA SALON 10-11: Relative Efficacy of Histopathology, IHC and RT-PCR to detect Occult Metastasis in Sentinel Lymph Nodes


• YERBA SALON 10-11: How Many Nodes are needed to Stage a Neck?


• YERBA SALON 10-11: Radiation and Cisplatin require an Immune Mechanism for Curing HPV + Cancer


• YERBA SALON 10-11: Planned Neck Dissection (PND) after Chemoradiotherapy in Locally Advanced Head & Neck Cancer


• YERBA SALON 10-11: Incidence of Regional Recurrences after Radiotherapy for Head & Neck Squamous Cell Carcinoma (HNSSC)


• YERBA SALON 10-11: Global Proteomic Analysis of HNSCC Identifies Prognostic Peptides


• YERBA SALON 10-11: Proinflammatory Mediators Upregulate Snail in HNSCC


• YERBA SALON 10-11: Defining an Epigenetic Continuum to Malignancy in Laryngeal Papillomatosis


• YERBA SALON 10-11: Triggering of TLR4 or TLR9 on Human Head & Neck Squamous Cell Carcinomas (HNSCC) Induces Distinct Biological Effects


• YERBA SALON 12-13: Minor Salivary Gland Carcinoma of Oropharynx and Oral Cavity


• YERBA SALON 12-13: 3D Tomosynthesis: Novel "Real-Time" Intraoperative Imaging Technology for Guidance of Skull Base Surgery


• YERBA SALON 12-13: Does Scar Length Really Matter in thyroid Surgery: a Prospective Randomized Clinical Trial


• YERBA SALON 12-13: Efficacy of Recurrent Laryngeal monitoring in an Otolaryngology Academic Training Program


• YERBA SALON 12-13: Elevated Postoperative PTH Levels in Primary Hyperparathyroidism


• YERBA SALON 12-13: Usefulness of Intraoperative Methylene Blue Infusion in Parathyroidectomy for Secondary Hyperparathyroidism


• YERBA SALON 12-13: Preoperative Localization of Parathyroid Adenomas Using SPECT-CT Imaging


• YERBA SALON 12-13: Paratracheal Neck Dissection: Indications, Technique, Surgical Results


• YERBA SALON 12-13: Comparison of Trends in Incidence and Mortality from thyroid Cancer in the UK and USA


• YERBA SALON 12-13: Outpatient Thyroidectomy: Experience in over 200 Patients


• YERBA SALON 12-13: Ultrasound of Cervical Lymph Nodes


• YERBA SALON 14: Carotenoids: Friend or Foe in Cancer Chemoprevention


• YERBA SALON 14: Tube Feeding in Head & Neck Cancer Patients Receiving Radiotherapy and Chemotherapy


• YERBA SALON 14: Complementary Serum Test of Antibodies to EBV EA+EBNA-1: a Possible Alternative for Primary Screening of NPC


• YERBA SALON 14: Does Neck Dissection after Chemoradiation therapy for Oropharyngeal Carcinoma Affect Swallowing Function?


• YERBA SALON 14: Influences and Predictors of Long-term Quality of Life in Head & Neck Cancer Survivors


• YERBA SALON 14: Merck-Serono: Honoraria for Lectures


• YERBA SALON 14: Auto-fluorescence screening for Oral Pre-malignant and Malignant Lesions


• YERBA SALON 14: Is EGG Based Videostroboscopic Assessment of To Speech Really Useful?


• YERBA SALON 14: Sequential Pattern of Plasma EBVDNA Copies in a Cohort of High Risk Non-NPC Patients


• YERBA SALON 14: Early Results of a Long-term Screening Program for Nasopharyngeal Carcinoma


• YERBA SALON 14: Swallowing Function Following Radiotherapy or Chemoradiotherapy for Advanced Stage Head & Neck Cancer


• YERBA SALON 14: Pharyngoesophageal Strictures in Head & Neck Cancer


• YERBA SALON 14: A Tale of Two Sites: Correlation of HPV Subtypes in SCCHN Patients and Cervix of Appalachian Women in West Virginia


• YERBA SALON 14: Parenteral vs. Enteral nutrition after Major Neck Surgeries


• YERBA SALON 14: Cigarette Smoke Regulates Reactive Oxygen Species Metabolism in the Larynx


• YERBA SALON 14: Smokescreens and Slights of Hand


• YERBA SALON 14: Genetic Analysis of Sporadic and Familiar Head & Neck Paraganglioma Tumors


• YERBA SALON 14: Nutrition & Dietetic Led Gastrostomy Pathway of Care for Insertion & Removal contributes to Outcomes


• YERBA SALON 14: Long-term Results of Provax ActiValve, Solving the Problem of Frequent Canida-and "underpressure"-related Voice Prosthesis Replacements


• YERBA SALON 15: Assessment of Quality of Life Following Anterior Skull Base Tumor Resection a Prospective Study


• YERBA SALON 15: Breaking Robustness: A Model for Head & Neck Cancer Progression


• YERBA SALON 15: The Effect of Autologous Platelet Adhesives on Dermal Fat Graft Resorption Following Reconstruction of a Superficial Parotidectomy


• YERBA SALON 15: EIF2c2 is Amplified and Over-expressed in HNSCC


• YERBA SALON 15: Low Level Expression of MicroRNA’s let7-d and miR-205 are Prognostic Markers of Head & Neck Squamous cell Carcinoma


• YERBA SALON 15: Gene expression Profiles Associated with Metastasis and Survival in Patients will Oral Tongue SCC


• YERBA SALON 15: Intra-tumoral Lymphatics Correlates with Regional Metastases in the Tongue Cancer


• YERBA SALON 15: Surgical Technique of "Facial Dismasking Approach" for Craniofacial Lesion


• YERBA SALON 15: Nomogram for Disease-specific Survival in HNSCC


• YERBA SALON 15: Genetic Expression Associated with Oral Cancer Identifies a Group of Patients at High-risk of Poor Survival


• YERBA SALON 15: Microvascular Free Tissue Transfer for Defects of the Scalp and Lateral Temporal Bone


• YERBA SALON 15: Endoscopic Dural Resection in the Management of Selected Sino-nasal Malignancies: Surgical Technique and Morbidity


• YERBA SALON 15: Preclinical Development of a Novel Cancer Cell Homing, PKCε Inhibitory Peptide for Head & Neck Cancer


• YERBA SALON 15: Parathyroid Carcinoma


• YERBA SALON 15: CT-MIBI Fusion Localization in Directed Parathyroidectomy


• YERBA SALON 15: Assessing the Impact of Variations in Baseline Parathyroid Hormone Levels on surgical Treatment of Primary Hyperparathyroidism


• YERBA SALON 15: 634 Directed Parathyroidectomies: Lessons Learned


• YERBA SALON 15: Ubc9 Expression by HNSCC: Correlation with Clinical Parameters and Proliferation


• YERBA SALON 15: Navigated Control: Surgical Assistance for Skull Base Surgery


• YERBA SALON 15: Results of Proton Beam Radiation therapy for Locally Advanced Squamous Cell Carcinoma (SCC) of the Paranasal Sinus and Nasal Cavity


• YERBA SALON 15: Clinical Outcomes of Sinonasal Cancer Treated with Endoscopic Endonasal Resection


• YERBA SALON 15: Treatment of Esthesioneuroblastoma with a Completely Endoscopic Endonasal Cranial Base Resection


• PACIFIC B: Session – LWP02. Cancer Prevention and Premalignancy


• PACIFIC C: CT/MR for Assessing Treatment Response


• PACIFIC C: Avoiding Pitfalls in the Post-Treatment Neck


• PACIFIC E: "Minimally Invasive" Paranasal Sinus-Cranial Base Surgery


• PACIFIC F: Non-PET-based Techniques for Functional H+N Imaging


• PACIFIC F: Imaging for Surveillance


• PACIFIC F: Imaging for surveillance Part II: Case Examples


• PACIFIC H: PET/CT in Neck Imaging: Practical Considerations


• PACIFIC H: PET in Head & Neck


• PACIFIC J: Ultrasound in Head & Neck Cancer Staging: Case Studies

• YERBA SALON 1-3: Mandibular Condyle Reconstruction with Fibular Free Tissue Transfer


• YERBA SALON 1-3: Versatility of the ALT Flap in Head & Neck Reconstruction


• YERBA SALON 1-3: Perioperative Airway Management in Patients receiving Oral cavity Free flap Reconstruction: Can Tracheotomy be Safely Avoided?


• YERBA SALON 1-3: Free Posterior Tibial Flap for Head & Neck Reconstruction after Tumor Resection


• YERBA SALON 1-3: Mandibular Defect Reconstruction with Composite Free Flaps and the Use of the 2.0 mm Unilock system


• YERBA SALON 1-3: Designing Chimera Flaps in Multiple Vascular systems


• YERBA SALON 1-3: Screening of Hypopharyngeal Cancer with the Hooded Videoendoscopy and the Narrow Band Imaging for Esophageal Cancer Patients


• YERBA SALON 1-3: Stereolithographic Biomodeling in Mandibular Reconstruction: a Prospective Trial


• YERBA SALON 1-3: Supraclavicular Artery Flap for Oncologic Head & Neck Reconstruction


• YERBA SALON 4-6: Salvage Surgery for Recurrent H&N Cancer


• YERBA SALON 4-6: Novel Strategies and Principles of Management of Recurrent Cancer of the Head & Neck


• YERBA SALON 4-6: Assaulting Therapeutic Barriers: Re-irradiation and Chemotherapy in Recurrent SCCHN


• YERBA SALON 4-6: Local Regional Recurrent Disease


• YERBA SALON 10-11: Immunostaining Patterns of CD31 and Podoplanin in Previously Untreated Advanced Oral/Oropharyngeal Cancer


• YERBA SALON 10-11: A Prospective Study of Surgical Margin Status in Oral Squamous Cell Carcinoma – A Preliminary Report


• YERBA SALON 10-11: Management of the Clinically No Neck in Oral and Oropharyngeal Carcinoma in Scotland


• YERBA SALON 10-11: Enhancement of Antitumor Activity Using Cetuximab and novel Epidermal Growth Factor Receptor (EGFR) Peptide-specific T Cells


• YERBA SALON 10-11: Identification of Stem-like Calls in Head & Neck Cancer Cell Lines


• YERBA SALON 10-11: The Toll-like Receptor 9 Agonist ODN1826 Inhibits Cachexia and Tumor Growth in Tumor-Bearing Mice


• YERBA SALON 10-11: Synergistic Effect of Resveratrol with Etoposide and Cisplatin in Merkel Cell Carcinoma Cell Lines


• YERBA SALON 10-11: Salivary Transcriptomes as Potential Early Detection Biomarkers for Oral Cancer


• YERBA SALON 10-11: Metastases to Level llb in Oral Cavity Cancer: A Systematic Review and Meta-analysis


• YERBA SALON 10-11: Vaccination with Ad E6/E7 Prevents HPV Related Cancer in Vivo


• YERBA SALON 10-11: Analysis of Risk Factors Predictive of Local Tumor Control in Oral Cavity Cancer


• YERBA SALON 10-11: Factor Contributing Need of Tracheostomy and Strategies to Overcome that in Patients Undergoing Oral and Oropharyngeal Cancer surgery


• YERBA SALON 10-11: Marginal Mandibulectomy for Buccal Sulcus Cancers: 10 Year Institutional Experience


• YERBA SALON 10-11: Sequential Therapy for Locally Advanced Larynx and Hypopharynx Cancer


• YERBA SALON 10-11: FGF2-retageted Adenoviral Gene Therapy for MRN Disruption Induces Cisplatin Chemosensitization for Head & Neck Cancer


• YERBA SALON 12-13: Autofluorescence Imaging and Molecular Markers combined, Provide a Robust Predictive Strategy in Oral Cavity Malingnancy


• YERBA SALON 12-13: The Role of Imaging Studies for the Detection of Retropharyngeal Lymph Node Metastasis in Head & Neck Cancer


• YERBA SALON 12-13: Detection of Pulmonary Tumours in Patients with Head & neck Squamous Cell Carcinoma at the time of Original Presentation


• YERBA SALON 12-13: Is there any Additional Value of SPECT/CT Over Lymphoscintigraphy for Sentinel node Mapping in Oral/Oropharyngeal SCC?


• YERBA SALON 12-13: Organ Preservation with Concurrent Chemoradiation for Advanced Laryngeal Cancer: Are We Succeeding?


• YERBA SALON 12-13: RECISTing the Neck: Interobserver Variability in the Use of RECIST Criteria for Neck Tumors


• YERBA SALON 12-13: PET-CT in the Management of Head & Neck Malignancies


• YERBA SALON 14-15: An Evaluation of Trends in the Quality of Research in the Subspecialty of Head & Neck Oncology


• YERBA SALON 14-15: Socioeconomic Status as a Predictor of Survival in Head & Neck Cancer Patients


• YERBA SALON 14-15: How Representative are Published Studies in Patients with Head & Neck Cancer of the Total Population of Patients?


• YERBA SALON 14-15: Are We Overestimating the Risk of Second Malignancies in Patients with Head & Neck Cancer?


• YERBA SALON 14-15: Second Primary Tumours in Laryngeal SCCs are not Associated with Poorer Overall Outcome and Survival


• YERBA SALON 14-15: Microvascular changes in Oral Mucositis


• YERBA SALON 14-15: Prospective Multicenter phase III Randomized Study Comparing Oral Pilocarpine vs. Submandibular Salivary gland Transfer Protocol for the Management of XRT Induced Xerostomia


• YERBA SALON 14-15: Telomerase Activity in Peripheral Whole Blood of Head & Neck Squamous Cell Carcinoma Patients Before and after Surgery


• YERBA SALON 14-15: Anon-invasive Diagnostic Technique Using Time-resolved Laser-induced Fluorescence Spectroscopy in the Hamster model


• YERBA SALON 14-15: A 3-D Interactive Pathology Visualization System


• YERBA SALON 14-15: Oral Cancer Trends Over Three Decades from 1984-2004 in the West Midlands, UK


• YERBA SALON 14-15: Bioengineered Human Salivary Tissue Constructs for the Treatment of Radiation Induced Xerostomia


• YERBA SALON 14-15: Trans Oral Robotic Surgery (TORS)


• PACIFIC A: Early Laryngeal Cancer


• PACIFIC B: T3N3 Tumor of the Hypopharynx: No Significant Comorbidities


• PACIFIC B: Induction Chemotherapy and Concomitant Chemoradiotherapy for Locoregionally Advanced Head & Neck Cancer


• PACIFIC C: Role of Surgery in the Palliative Treatment of Head & Neck Carcinoma


• PACIFIC E: Practice Guidelines: Cost Control in Head & Neck Cancer


• PACIFIC E: Organ Preservation in Brazil. Can We Afford It?


• PACIFIC F: Symptom control for Non-Surgical Treatments


• PACIFIC H: Progress in Medical Treatment of Incurable Salivary Gland and Thyroid Cancers


• PACIFIC H: Novel Agents in Thyroid Cancer


• PACIFIC I: Angiogenesis Inhibition in HNSCC


• PACIFIC J: Target Therapy. Kinase Inhibition.

• YERBA SALON 1-3: Biomarkers in Oral Dysplasia: A systematic Review


• YERBA SALON 1-3: Unilateral Thyroid Lobectomy for Differentiated thyroid Carcinoma


• YERBA SALON 1-3: Marginal Mandibular Nerve Injury in Neck Dissection and its Impact on Patient Perception of Appearance


• YERBA SALON 1-3: Comparing Prognostic Outcomes of Tall Cell Variant to Normal Variant Papillary Thyroid Carcinoma: a Meta-analysis


• YERBA SALON 1-3: Early Experience Using Time - and Swept Source Frequency domain Optical coherence Tomography in Head & Neck Oncology


• YERBA SALON 1-3: The Influence of Passive vs Suction Drainage on Complications Following Neck Dissection


• YERBA SALON 1-3: Substernal Goiters and Sternotomy


• YERBA SALON 1-3: Outcomes of Untreated Papillary Thyroid Cancer


• YERBA SALON 1-3: Molecular Imaging of Sentinel Lymph Mode Metastases Using Oncolytic Herpes Simplex Virus-mediates Transgene Expression


• YERBA SALON 1-3: Surgical Management of Well Differentiated Thyroid Carcinoma


• YERBA SALON 1-3: Colour Flow Doppler and the Anterolateral Thigh Flap: Clinical Utility


• YERBA SALON 1-3: Risk-adjusted Use of FDG-PET/CT in Radiation Response Assessment for HNSCC


• YERBA SALON 1-3: Shoulder Morbidity Following Pectoralis Major Flap Reconstruction


• YERBA SALON 1-3: Chemo-selection as a Strategy for Organ Preservation


• YERBA SALON 1-3: Geldanamycin Treatment Radiosensitize Head & Neck Carcinoma Cells by Promoting EGFR Degradation


• YERBA SALON 1-3: ICC 2302: Phase II Study of Combretastatin A4 Phosphate (CA4P, Fosbretabulin) on Advanced Anaplastic Thyroid Carcinoma


• YERBA SALON 1-3: Complications of total Thyroidectomy in Benign vs Maligant Disease


• YERBA SALON 1-3: Comparison of Post-operative Complications after Thyroidectomy with and without Central Compartment Dissection


• YERBA SALON 1-3: Papillary Thyroid Cancer in Children: Management and Patterns of Failure


• YERBA SALON 4-6: Neuroradiology of Nasopharyngeal Cancer Diagnosis and Patterns of Spread


• YERBA SALON 4-6: Chemo/IMRT. IMRT-Debates


• YERBA SALON 4-6: The Radiation Oncologists Cannot Reproducibly Choose What to Treat


• YERBA SALON 4-6: IMRT, Especially when Combined with Chemo, is too Toxic and Dangerous


• YERBA SALON 4-6: Conclusions


• YERBA SALON 4-6: Chemo/IMRT is either too Toxic or too Dangerous… The Cons…


• YERBA SALON 4-6: Nasopharyngeal Cancer


• YERBA SALON 4-6: IMRT in the Treatment of Nasopharyngeal Carcinoma (NPC)


• YERBA SALON 4-6: Nasopharyngeal Cancer


• YERBA SALON 4-6: Nasopharyngeal Carcinoma: Recurrent Metastatic and biologic Targeted therapy


• YERBA SALON 10-11: Expression of CD24, EGFR, and MDM2 Predict Disease Specific Survival in Patients with Advanced Laryngeal Cancer


• YERBA SALON 10-11: Response to Induction Chemotherapy and Chemoradiation is Predicted by Low Expression of BAK and NFkB in Patients with Advanced Laryngeal Cancer


• YERBA SALON 10-11: Shoulder Morbidity after Surgical and Non-surgical Treatment of the Neck


• YERBA SALON 10-11: Expression of Hedgehog Signaling Molecules in Merkel Cell Carcinoma


• YERBA SALON 10-11: The Clinical Significance of Loss of Heterozygosity in Head & Neck Squamous Cell Carsinoma


• YERBA SALON 10-11: Molecular Staging of Surgically Treated Head & Neck Cancer Patients


• YERBA SALON 10-11: Improved Outcome with Neck Dissection Following Chemoradiation for N3 Disease


• YERBA SALON 10-11: Positron Emission Tomography in the Management of Head & Neck Cancer of Unknown Primary


• YERBA SALON 10-11: Quality of Life after Neck Dissection


• YERBA SALON 10-11: Diffusion-weighted MRI for Nodal Staging of Locally Advanced Head & Neck Squamous Cell Carcinoma: Impact on Radiotherapy Planning


• YERBA SALON 10-11: DCE-MRI Perfusion Imaging of HNSCC Nodal Metastasis


• YERBA SALON 10-11: The Prognostic Significance of Tumour HIF-1a Expression for Outcome Following Radiotherapy in Oropharyngeal Cancer


• YERBA SALON 10-11: Initial Staging of the Neck in HNSCC: is PET/CT the best?


• YERBA SALON 10-11: FcγIIIA Polymorphisms and Cetuximab Induced Cytotoxicity in SCCHN


• YERBA SALON 10-11: The role of PGP9.5 as a Tumor Suppressor Gene in Head & Neck Cancer


• YERBA SALON 10-11: Ultrasound Guided Aspiration Cytology for the Assessment of the clinical NO Neck; Factors Influencing its Accuracy


• YERBA SALON 12-13: Low Molecular Weight Heparin Thromboprophylaxis and Bleeding risk in Head & Neck Cancer Microvascular Reconstruction


• YERBA SALON 12-13: Mandibular Reconstruction with Autologus Freeze-treated Bone after Malignant Tumor Resection


• YERBA SALON 12-13: Free Jejunum Versus Tubed Flaps for Total Laryngopharyngectomy Defects: Patterns of Use and Outcomes


• YERBA SALON 12-13: A New Option in Maxillary Reconstruction


• YERBA SALON 12-13: Microvascular Reconstruction in the Setting of Prior Intra-arterial Chemotherapy with Concomitant Radiation


• YERBA SALON 12-13: Reconstruction of Maxillary Defects-options and Outcome


• YERBA SALON 12-13: Bone Impacted Fibula (BIF)


• YERBA SALON 12-13: Radial Forearm Versus Anterolateral Thigh Free Flaps for Laryngopharyngectomy Defects


• YERBA SALON 12-13: A Practical Approach to Maxillary Reconstruction Based Upon the Patient’s Desire for Dental Rehabilitation


• YERBA SALON 12-13: Combinatorial therapy for Healing Cranial Defects Compromised by Preoperative Radiation


• YERBA SALON 12-13: A Prospective Analysis of Factors Predicting Morbidity in Microvascular Free Flap Reconstruction of the Head & Neck


• YERBA SALON 12-13: Pectoralis Myofascial Flap During Salvage Laryngectomy Prevents Pharyngocutaneous Fistula


• YERBA SALON 12-13: The Use of Radial Forearm Free Flap for total Lower Lip Reconstruction


• YERBA SALON 12-13: The Role of Salvage Surgery in Recurrent Oropharyngeal Squamous Cell Carcinoma


• YERBA SALON 12-13: Efficacy of Low Molecular Weight Heparin in Preventing Free Flap Failure: A Rat Model


• YERBA SALON 12-13: The Use of Stress-Shielding Reconstruction Plates in Free Fibula Mandible Reconstruction May be Associated with Increase Rates of Bone Resorption


• YERBA SALON 14-15: Random Positional Variation Amongst the Skull, Mandible and cervical Spine in Daily Setup for Head & Neck Radiotherapy


• YERBA SALON 14-15: Laser Vestibulectomy for Supraglottic Carsinomas


• YERBA SALON 14-15: Laser Surgery of Early Glottic Cancer


• YERBA SALON 14-15: Predictors of outcome for Advanced Stage Supraglottic Laryngeal cancer


• YERBA SALON 14-15: Two-Year Longitudinal Study of Swallowing After Chemotherapy-IMRT for Head & Neck Cancer


• YERBA SALON 14-15: Complications and Findings in Panendoscopy of Chemoradiated Patients


• YERBA SALON 14-15: Endoscopic C02 Laser Supraglottic Laryngectomy Multicenter Analysis of 144 cases


• YERBA SALON 14-15: Treatment of Pharyngeal carcinomas by Laser Endoscopic Microsurgery


• YERBA SALON 14-15: Clinical Impact of Introducing Supracricoid Laryngectomy with CHEP


• YERBA SALON 14-15: Do Team Member Managing Head & Neck Cancer Have the same or different Views when Predicting Quality of Life?


• YERBA SALON 14-15: Functional Outcomes and Quality of Life


• YERBA SALON 14-15: Clinical Predictors of Survival with Functional Larynx Preservation after Multiagent Concurrent Chemotherapy and Radiation


• YERBA SALON 14-15: Validation of the EORTC Quality of life Instruments in Laryngeal Cancer Patients after Surgery


• YERBA SALON 14-15: Interstitial PDT in Recurrent Head & Neck Carcinoma


• YERBA SALON 14-15: Phonosurgical Treatment of Early Glottal Cancer: Innovations Through the Past 15 Years


• PACIFIC B: Hypoxia Research and clinical Practice


• PACIFIC B: Secreted & Tissue Markers for Hypoxia & Prognosis in Head & Neck Cancer


• PACIFIC E: Proton Beam Radiation for Head & Neck Cancer


• PACIFIC H: Current Strategies for Management of XRT Induced Xerostomia


• PACIFIC J: Orbital and Periorbital Hemangiomas and Vascular Malformations

• YERBA SALON 1-3: Prevalence of K-RAS Codon 12 Mutations in Locally Advanced Head & Neck Squamous Cell Carcinoma and Impact on clinical Outcomes


• YERBA SALON 1-3: RT-PCR for Cytokeratin 20 for Molecular Diagnosis of Lymphatic Metastases in Patients with Head & Neck Cancer


• YERBA SALON 1-3: Heparanase Induces VEGF-C Levels and Facilitates Tumor Lymphangiogenesis


• YERBA SALON 1-3: Immunology and Stem Cells - the Dysfunctional Tumor Microenviroment as a Barrier to Successful Therapy


• YERBA SALON 1-3: SCCHN Can Induce T Cell Senescence as a Novel form of Immune Escape


• YERBA SALON 1-3: PGE² Production is Enhanced in UV Exposed Keratinocytes: Evidence for the Role of 15-Hydroxyprostaglandin Dehydrogenase


• YERBA SALON 1-3: Tetrathiomolybdate inhibits Head & Neck cancer Metastasis by Decreasing Tumor Cell Invasion & Promoting Tumor Cell Anoikis


• YERBA SALON 1-3: Oncolytic Herpes Simplex Virus OncoVEX(GALV/CD) Prodrug Activation Enhances Viral Cytotoxicity in Head & Neck Squamous Cell Carcinoma


• YERBA SALON 1-3: Cancer Stem Cells in Head & Neck Cancer


• YERBA SALON 1-3: Lymphocyte Homing Receptor/Tumor Ligand Interactions: a Putative Mechanism for Promoting Immune Tolerance


• YERBA SALON 1-3: Prediction of Local Recurrence after Radiotherapy for Larynx Carcinoma Using Tissue array Immunohistochemistry


• YERBA SALON 1-3: Inflammatory and Pattern Recognition Receptors Expressed by Cancer Cells


• YERBA SALON 1-3: EGFRvIII Induces HNSCC Tumor Cell Migration and Invasion via Activation of STAT3


• YERBA SALON 4-6: Surgery for Preservation of Swallowing


• YERBA SALON 4-6: The Role of p53 Mutations in Mouse Models for Oral Cancer


• YERBA SALON 4-6: Measuring and Quantifying Dysphasia


• YERBA SALON 4-6: Orthotopic Models of Head & Neck Cancer Including Oral SCCA, Thyroid CA, & Salivary CA


• YERBA SALON 4-6: Swallowing


• YERBA SALON 4-6: Swallowing and Quality of Life


• YERBA SALON 4-6: Panel: Mouse Model for Head & Neck Cancer


• YERBA SALON 4-6: Dissecting Genetic Alterations and Microenvironment Contributing to HNSCC using Mouse Tumors as model System


• YERBA SALON 10-11: Gene Expression and Promoter Polymorphisms of DNMT3B in NPCs in Taiwan: A Case-Control Study


• YERBA SALON 10-11: Early Oral Feeding after Salvage Laryngectomy


• YERBA SALON 10-11: The Role of Induction Chemotherapy for the Management of Sinonasal Undifferentiated Carcinoma


• YERBA SALON 10-11: Oropharyngeal SCC. Is there a Role for Primary Surgery?


• YERBA SALON 10-11: Wide Vertical Hemipharyngolaryngectomy for Laryngopharyngeal Cancer: Revised Surgical Technique & Classification


• YERBA SALON 10-11: Conservative Management of Iatrogenic Esophageal Perforation in Head & Neck Cancer Patients with Esophageal Stricture


• YERBA SALON 10-11: Supracricoid Partial Laryngestomy after Radiation Failure


• YERBA SALON 10-11: Endoscopic Treatment for T1-T3 Supraglottic Cancer: a Multi-institutional Series of 127 Patients


• YERBA SALON 10-11: Stereotactic Radiosurgery for Head & Neck and Skull Base Cancer


• YERBA SALON 10-11: PET/CT in Previously Treated Skull Base Malignancies


• YERBA SALON 10-11: Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma


• YERBA SALON 10-11: Speech and Swallowing Following Microsurgical Reconstruction of Soft Palate


• YERBA SALON 10-11: Salvage Laryngectomy Following Organ Preservation Protocols


• YERBA SALON 10-11: Fascia-only Free Radial Forearm Flap for Resurfacing the Nasopharynx Following Nasopharyngectomy


• YERBA SALON 10-11: Endoscopic Transpterygoid Nasopharyngectomy for the Treatment of Nasopharyngeal Carcinoma


• YERBA SALON 10-11: Changing Treatment Paradigms in the Management of Squamous Cell Carcinoma of the Supraglottic Larynx


• YERBA SALON 12-13: Squamous Cell carcinoma of Oral Tongue (SCCT) in Young Adults


• YERBA SALON 12-13: Swallowing Function after Intensity-Modulated and Concomitant Boost Radiation Therapy for Oropharyngeal Carcinoma


• YERBA SALON 12-13: Assessment of Mouth Self Examination for Early Detection of Oral Cancer in a High-risk Population


• YERBA SALON 12-13: Prediction of Treatment Complications in Patients with Oropharyngeal Cancer


• YERBA SALON 12-13: Treatment and Follow-up of Oral Dysplasia


• YERBA SALON 12-13: Radiotherapy as Single-modality Treatment for Head & Neck Paragangliomas


• YERBA SALON 12-13: Functional Organ Preservation in T4 Laryngeal/Hypopharyngeal Cancer Treatment with Chemoradiation


• YERBA SALON 12-13: The Pattern of Failure after Re-irradiation of Recurrent Head & Neck Cancer: Sqamous Cell Cancer (HNSCC)


• YERBA SALON 12-13: Squamous Cell Carcinoma Regional Metastases Treated with Radiation Therapy: Correlation Between CT and Histology


• YERBA SALON 12-13: Encouraging Presentation of Oral Cancer in a High Risk Group


• YERBA SALON 12-13: Utilizing 5-Aminolevulinic Acid and Pulsed Dye Laser for Photodynamic therapy (PDT) of Oral Leukoplakia


• YERBA SALON 12-13: Lack of Association Between HPV Infection and Oral Tongue Carcinoma in Young and Older Adults


• YERBA SALON 12-13: A Population-based Analysis of the Association of Oral/Pharyngeal Carcinomas with HPV-Related Anogenital Carcinomas in Men


• YERBA SALON 12-13: Xerostomia in Patients with Head & Neck Tumors Treated by IMRT: Importance of Absolute Spared Parotid Volume


• YERBA SALON 12-13: Radical Radiation for Unknown Primary Squamous Cell Cancer Yields high Control but has Major Toxicity Suggesting Need for New Treatment Parading


• YERBA SALON 12-13: A Food-based Approach to Oral Cancer Chemoprevention


• YERBA SALON 12-13: Dosimetric Uncertainties in Matched IMRT and Conventional Fields for Head & Neck Cancer Radiotherapy


• YERBA SALON 14-15: "Dual disruption" Therapy for Head & Neck Cancer: Targeting DNA Repair Pathways to Induce Cancer Cell Death


• YERBA SALON 14-15: Cisplatin and JSI-124 Induce Synergistic Cell Death in a Cisplatin Resistant Cell Line


• YERBA SALON 14-15: Peri-tumoral Injections of Purified Tumstatin Delay Tumor Growth & Lymphatic Metastasis in an Orthotopic Oral SCC Model


• YERBA SALON 14-15: Single-walled Carbon Nanotubes Associated with Paclitaxel Inhibit the Growth of Head & Neck Squamous Cell Tumors


• YERBA SALON 14-15: Salvage Surgery for Recurrent Nasopharyngeal Carcinoma Using a Partial Maxillectomy Approach


• YERBA SALON 14-15: Metronomic Administration of a Small Molecule Inhibitor of Bcl-2 Combined with Cisplatin in Xenografted Head & Neck Cancer


• YERBA SALON 14-15: Sensitization of Head & Neck Cancer Cells to Cisplatin is Potentiated by Genistein


• YERBA SALON 14-15: Preclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head & Neck


• YERBA SALON 14-15: Hyaluronan and CD44 Interact with RHO-kinase and PI 3-kinase to Promote Gowth, Migration, Invasion, and Cisplatin Resistance in HNSCC


• YERBA SALON 14-15: Assessment of EGFR Inhibition by Erlotinib in Tumors as Compared with normal Mucosa in Patients with Oral Cavity Squamous Cell Carcinoma